Compare CALC & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | RSSS |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.3M | 93.0M |
| IPO Year | N/A | N/A |
| Metric | CALC | RSSS |
|---|---|---|
| Price | $5.40 | $2.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $16.00 | $5.00 |
| AVG Volume (30 Days) | ★ 96.2K | 49.6K |
| Earning Date | 11-12-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $49,325,684.00 |
| Revenue This Year | N/A | $4.92 |
| Revenue Next Year | N/A | $7.09 |
| P/E Ratio | ★ N/A | $70.27 |
| Revenue Growth | N/A | ★ 5.83 |
| 52 Week Low | $1.42 | $2.32 |
| 52 Week High | $7.20 | $4.12 |
| Indicator | CALC | RSSS |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 45.88 |
| Support Level | $5.05 | $2.78 |
| Resistance Level | $5.71 | $2.95 |
| Average True Range (ATR) | 0.70 | 0.10 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 16.74 | 40.88 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.